The global large and small-scale bioprocessing market size was estimated at USD 80.5 billion in 2024 and is expected to reach USD 228.7 billion by 2033, growing at a CAGR of 11.86% from 2025 to 2033.  The impressive rise in market size is largely fueled by the escalating worldwide demand for biologic products. These biologics include a broad range of therapies such as monoclonal antibodies, vaccines, as well as cutting-edge cell and gene therapies. The growing adoption of these advanced therapeutic products across various healthcare sectors is a key factor driving the expansion of the bioprocessing market.

Additionally, biopharmaceutical companies are channeling considerable investments into adopting flexible manufacturing solutions. Innovations like single-use technologies, which allow for disposable and adaptable components in production, and modular bioprocessing systems, which enable scalable and easily reconfigurable manufacturing setups, are gaining widespread use. These technologies play a crucial role in accelerating the development timelines for new therapies and significantly reducing overall production costs, thereby supporting the sustained growth of the bioprocessing industry worldwide.

Key Market Trends & Insights:

• In 2024, the bioprocessing market in North America, encompassing both large and small-scale operations, dominated the global landscape by holding the largest market share of 34.84%. This significant portion highlights the region’s strong presence and influence in the bioprocessing industry worldwide.

• Within North America, the United States emerged as the leading country, driving the market forward with its advanced large and small-scale bioprocessing industry. The U.S. has been pivotal in maintaining the region’s market leadership due to its robust infrastructure, technological advancements, and substantial investments in bioprocessing capabilities.

• When analyzing the market based on workflow stages, the downstream processing segment accounted for the highest market share at 46.85% in 2024. This indicates that a considerable portion of the market’s focus and revenue is concentrated on the purification and recovery stages that follow upstream bioprocessing activities.

• Looking at the product categories within this market, bioreactors and fermenters stood out by capturing the largest market share of 29.10% in 2024. These products are critical components in the bioprocessing workflow, facilitating the growth of microorganisms or cells used in various biotechnological applications.

• Finally, considering the scale of operations, the industrial scale segment, defined as facilities with a capacity exceeding 50,000 liters, held the highest market share in 2024. This reflects the trend towards large-scale bioprocessing production, which supports mass manufacturing of biopharmaceuticals and other bioproducts on a global scale.

Order a free sample PDF of the Large And Small-scale Bioprocessing Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 80.5 Billion

• 2033 Projected Market Size: USD 228.7 Billion

• CAGR (2025-2033): 11.86%

• North America: Largest market in 2024

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

The global market for large and small-scale bioprocessing is characterized by a dynamic blend of well-established global leaders alongside emerging specialized companies. Together, they contribute to a rapidly changing and innovative industry landscape. This transformation is primarily driven by advancements in biopharmaceutical innovation, increasing demand for cell and gene therapies, and a surge in worldwide biologics production.

Major players such as Merck KGaA, Thermo Fisher Scientific, GE Healthcare, Sartorius AG, and Lonza have secured a significant presence in the market. These companies have achieved this through extensive and diverse product portfolios, large-scale manufacturing capabilities, and consistent investment in cutting-edge bioprocessing technologies and automation solutions. Their leadership helps set industry standards and drives technological progress within the sector.

At the same time, companies based in Asia and Europe—such as Samsung BioLogics, Binex Co., Ltd., Rentschler Biopharma, and Inno Biologics—are expanding their global footprint by capitalizing on regional manufacturing strengths and forging strategic alliances with major pharmaceutical corporations worldwide. This enables them to tap into growing international markets and enhance production capabilities.

In addition, several niche companies like Bioprocess Control AB, Bio-Process Group, and TOYOBO Co., Ltd. play a crucial role by providing specialized technologies focused on process analytics and upstream process optimization. These innovations are essential for smaller biotech firms and research organizations, as they enable these entities to efficiently scale their bioprocessing operations and accelerate development timelines, thereby supporting broader market growth and diversification.

Key Players

• Merck KGaA

• Thermo Fisher Scientific, Inc.

• Danaher (Cytiva)

• Corning Inc.

• Sartorius AG

• Lonza

• CESCO BIOENGINEERING CO., LTD

• Bio-Process Group

• BPC Instruments AB

• Eppendorf AG

• Getinge AB

• PBS Biotech, Inc.

• Bio-Synthesis, Inc.

• Meissner Filtration Products, Inc.

• Entegris

• KUHNER AG

• Saint-Gobain

• ExcellGene SA

• Repligen Corporation

• Avantor, Inc

• CerCell A/S

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The large and small-scale bioprocessing market is experiencing significant growth, primarily driven by the increasing demand for biologics such as monoclonal antibodies, vaccines, and cell and gene therapies. This surge is further fueled by the rising prevalence of chronic diseases, an aging population, and the push for personalized medicine. Technological advancements, including the adoption of single-use technologies and modular systems, are enhancing manufacturing efficiency and flexibility.